Emerging Drugs and Targets for Alzheimer\'s Disease, Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism
￥ 880 九品
仅1件
河北保定
认证卖家担保交易快速发货售后保障
作者Martinez, Ana
出版社Royal Society of Chemistry
ISBN9781849730631
出版时间2010-05
装帧平装
页数317页
上书时间2013-12-26
- 在售商品 暂无
- 平均发货时间 16小时
- 好评率 暂无
- 店主推荐
- 最新上架
商品详情
- 品相描述：九品
- 商品描述
-
精装书 作者： Martinez, Ana 页数： 317 页 出版于： 20100507 ISBN13： 9781849730631 ISBN10： 1849730636 出版社： RSC Publishing 规格： 240 x 165 x 23 mm 重量： 635 克
Alzheimer\\\'s disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease\\\'s progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer\\\'s disease.
Emerging Drugs and Targets for Alzheimer\\\'s Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer\\\'s drug market over the next few years as disease modifying drugs.
Written by a team of distinguished experts Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism will be an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.
— 没有更多了 —
以下为对购买帮助不大的评价